Short seller report sparks legal scrutiny and dividend update for Ensign Group stock

Ensign Group (ENSG) has been thrust into the spotlight after a Hunterbrook short seller report alleged inadequate patient care, manipulation of quality metrics, and misuse of taxpayer funds, prompting multiple law firm investigations.

Against this backdrop, Ensign Group also declared a quarterly cash dividend of $0.0650 per share, payable on or before July 31, 2026, to shareholders of record as of June 30, 2026.

Ensign Group’s share price has been under pressure in recent months, with a 30 day share price return down 8.82% and a 90 day share price return down 22.74%, even as the 1 year total shareholder return is 3.18% and the 5 year total shareholder return is 77.69%.

If this mix of legal risk and capital returns has you reassessing your portfolio, it could be a good moment to broaden your watchlist with 38 healthcare AI stocks

With Ensign Group shares down over the past quarter but still positive over 1 and 5 years, along with active dividends and buybacks, are investors looking at undervalued legal risk or a stock where the market already prices in future growth?

Preferred P/E of 25x: Is it justified for Ensign Group?

On current figures, Ensign Group trades on a P/E of 25x, which screens as expensive compared with both its own fair P/E estimate and several benchmarks.

The P/E multiple links the $156.78 share price to earnings, so it reflects what investors are willing to pay today for each dollar of Ensign Group’s profit.

Here, the company is described as expensive versus the estimated fair P/E of 23.4x and also compared with the US Healthcare industry average of 23.4x and a peer group average of 13.9x. That suggests the market is paying up for Ensign Group’s earnings, even though its forecast revenue and earnings growth are below broader US market forecasts and its current 15.3% return on equity is labelled low.

The contrast is sharper when set alongside the SWS DCF view, which indicates Ensign Group at $156.78 is trading about 4.5% below an estimated future cash flow value of $164.13, and analysts who broadly expect the stock price to rise by 40.6% from here with a $220.40 target price.

Result: Price-to-earnings of 25x (OVERVALUED)

However, ongoing legal investigations and concerns around Ensign Group’s reported quality of care could still shift sentiment and challenge the current P/E premium that investors are paying.

Another view on Ensign Group’s valuation

While Ensign Group looks expensive on a 25x P/E, the SWS DCF model points in a different direction, suggesting the stock at $156.78 trades about 4.5% below an estimated future cash flow value of $164.13. If earnings unfold as expected, is the market being too cautious, or just early?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ensign Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Ensign Group split between legal risk and potential upside, it makes sense to move quickly and test the numbers yourself rather than rely on headlines alone. To weigh those concerns against what the market still likes about the stock, start by reviewing its 4 key rewards

Looking for more investment ideas beyond Ensign Group?

If the Ensign Group story has you reassessing your approach, this is the moment to widen your search rather than wait and watch opportunities pass by.

• Target income-focused opportunities by scanning companies that appear in the 7 dividend fortresses that may suit investors who want yield alongside potential stability.
• Spot potential value setups by reviewing the 44 high quality undervalued stocks and see which stocks currently flag as high quality on both earnings strength and pricing.
• Prioritize resilience by checking companies highlighted in the 66 resilient stocks with low risk scores if you want businesses with lower risk scores at the core of your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.